重大血管手术后出现的正常血糖性糖尿病酮症酸中毒是术后酸中毒鉴别诊断中的一个新项目。
Euglycemic diabetic ketoacidosis following major vascular surgery is a new item on the differential for postoperative acidosis.
作者信息
Gomez-Sanchez Clara M, Wu Bian X, Gotts Jeffrey E, Chang Robert W
机构信息
Division of Vascular and Endovascular Surgery, Department of Surgery, University of California San Francisco, San Francisco, Calif.
Department of Vascular Surgery, Kaiser Permanente Northern California, Oakland, Calif.
出版信息
J Vasc Surg Cases Innov Tech. 2021 Oct 22;7(4):778-780. doi: 10.1016/j.jvscit.2021.10.006. eCollection 2021 Dec.
Abstract
New pharmacologic advances in the treatment of diabetes include SGLT-2 inhibitors, which have been demonstrated in randomized-controlled clinical trials to reduce overall and cardiac-specific mortality and slow progression of chronic kidney disease. Euglycemic diabetic ketoacidosis is a rare but life-threatening complication associated with the use of SGLT-2 inhibitors. Here we describe a case of severe euglycemic diabetic ketoacidosis after lower extremity bypass in a patient taking an SGLT-2 inhibitor. Awareness of this potential complication is essential as these novel agents are increasingly used in patients with cardiovascular disease.
摘要
糖尿病治疗方面的新药理学进展包括钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂，随机对照临床试验已证明其可降低总体死亡率和心脏特异性死亡率，并减缓慢性肾脏病的进展。正常血糖性糖尿病酮症酸中毒是一种与使用SGLT-2抑制剂相关的罕见但危及生命的并发症。在此，我们描述了1例服用SGLT-2抑制剂的患者在下肢搭桥术后发生严重正常血糖性糖尿病酮症酸中毒的病例。鉴于这些新型药物越来越多地用于心血管疾病患者，认识到这一潜在并发症至关重要。
相似文献
1
Euglycemic diabetic ketoacidosis following major vascular surgery is a new item on the differential for postoperative acidosis.重大血管手术后出现的正常血糖性糖尿病酮症酸中毒是术后酸中毒鉴别诊断中的一个新项目。
J Vasc Surg Cases Innov Tech. 2021 Oct 22;7(4):778-780. doi: 10.1016/j.jvscit.2021.10.006. eCollection 2021 Dec.
2
Euglycemic Ketoacidosis Associated with SGLT-2 Inhibitors in Non-diabetic Patients-A Narrative Review.非糖尿病患者中与SGLT-2抑制剂相关的正常血糖性酮症酸中毒——一篇叙述性综述
J Gen Intern Med. 2025 Feb;40(2):437-442. doi: 10.1007/s11606-024-09073-2. Epub 2024 Oct 1.
3
Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.恩格列净治疗的 2 型糖尿病患者发生多因素病因的严重血糖正常性糖尿病酮症酸中毒：病例报告及文献复习。
BMC Nephrol. 2020 Jul 15;21(1):276. doi: 10.1186/s12882-020-01930-6.
4
A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis.一例罕见的因恩格列净诱发的正常血糖性糖尿病酮症酸中毒被碱中毒掩盖的病例。
Cureus. 2022 Jun 10;14(6):e25818. doi: 10.7759/cureus.25818. eCollection 2022 Jun.
5
Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.一名27岁1型糖尿病女性患者使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂卡格列净治疗后出现正常血糖性糖尿病酮症酸中毒。
Pak J Med Sci. 2016 May-Jun;32(3):786-8. doi: 10.12669/pjms.323.9201.
6
Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report.同时采用极低碳水化合物饮食和使用钠-葡萄糖协同转运蛋白2抑制剂时出现的正常血糖性糖尿病酮症酸中毒：一例报告
Clin Pract Cases Emerg Med. 2020 Apr 23;4(2):185-188. doi: 10.5811/cpcem.2020.2.45904. eCollection 2020 May.
7
8
Euglycemic Diabetic Ketoacidosis, Recurrent Genital Abscess, and Proximal Renal Tubular Acidosis With Concurrent SGLT-2 Inhibitor: More Than an Association.正常血糖性糖尿病酮症酸中毒、复发性生殖器脓肿与近端肾小管酸中毒合并SGLT-2抑制剂：不仅仅是一种关联。
Cureus. 2024 Aug 22;16(8):e67481. doi: 10.7759/cureus.67481. eCollection 2024 Aug.
9
[Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].[2型糖尿病患者使用SGLT2抑制剂治疗后出现的糖尿病正常血糖性酮症或酮症酸中毒：比利时系列临床病例]
Rev Med Interne. 2020 Apr;41(4):226-231. doi: 10.1016/j.revmed.2019.12.006. Epub 2019 Dec 19.
10
Late-Onset Euglycemic Diabetic Ketoacidosis in a Patient With Massive Stroke Requiring Decompressive Craniectomy: A Case Report.一名需要进行减压性颅骨切除术的大面积中风患者发生迟发性血糖正常的糖尿病酮症酸中毒：病例报告
Cureus. 2021 Oct 9;13(10):e18629. doi: 10.7759/cureus.18629. eCollection 2021 Oct.
引用本文的文献
1
Sodium-Glucose Cotransporter-2 Inhibitors and Euglycemic Diabetic Ketoacidosis: A Case Series of Three Post-surgical Patients.钠-葡萄糖协同转运蛋白2抑制剂与正常血糖性糖尿病酮症酸中毒：三例外科手术后患者的病例系列
Cureus. 2025 May 23;17(5):e84665. doi: 10.7759/cureus.84665. eCollection 2025 May.
2
Euglycemic Diabetic Ketoacidosis in the Setting of Dulaglutide Use.使用度拉糖肽时出现的正常血糖性糖尿病酮症酸中毒
Cureus. 2025 Apr 12;17(4):e82143. doi: 10.7759/cureus.82143. eCollection 2025 Apr.
3
Sodium-glucose cotransporter 2 inhibitor-induced postoperative euglycaemic diabetic ketoacidosis after pancreatectomy.钠-葡萄糖协同转运蛋白2抑制剂诱发胰腺切除术后正常血糖性糖尿病酮症酸中毒
Br J Surg. 2023 Apr 12;110(5):545-547. doi: 10.1093/bjs/znad044.
4
Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports.钠-葡萄糖共转运蛋白 2 抑制剂相关围手术期酮症酸中毒：病例报告的系统评价。
J Anesth. 2023 Jun;37(3):465-473. doi: 10.1007/s00540-023-03174-8. Epub 2023 Feb 27.
5
New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature.新型糖尿病药物钠-葡萄糖协同转运蛋白2抑制剂可诱发正常血糖性酮症酸中毒并酷似外科疾病：一例报告及文献复习
Front Surg. 2022 Mar 24;9:828649. doi: 10.3389/fsurg.2022.828649. eCollection 2022.
本文引用的文献
1
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.SGLT2 抑制剂与 2 型糖尿病患者心血管和肾脏结局的关联：一项荟萃分析。
JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511.
2
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.依帕列净对 2 型糖尿病合并已确诊动脉粥样硬化性心血管疾病患者心力衰竭相关事件的疗效：VERTIS CV 试验结果。
Circulation. 2020 Dec 8;142(23):2205-2215. doi: 10.1161/CIRCULATIONAHA.120.050255. Epub 2020 Oct 7.
3
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.基于基线肾功能的坎格列净的肾脏、心血管和安全性结局：CREDENCE 随机试验的二次分析。
J Am Soc Nephrol. 2020 May;31(5):1128-1139. doi: 10.1681/ASN.2019111168.
4
Summary of Revisions: .修订摘要：
Diabetes Care. 2020 Jan;43(Suppl 1):S4-S6. doi: 10.2337/dc20-Srev.
5
Global vascular guidelines on the management of chronic limb-threatening ischemia.全球血管指南：慢性肢体威胁性缺血的管理。
J Vasc Surg. 2019 Jun;69(6S):3S-125S.e40. doi: 10.1016/j.jvs.2019.02.016. Epub 2019 May 28.
6
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
7
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.恩格列净降低了 EMPA-REG OUTCOME 试验中各种心血管风险患者的死亡率和心力衰竭住院率。
Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.
8
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.达格列净与 2 型糖尿病患者的心血管结局
N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
9
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
10
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：对原发性文献中糖尿病酮症酸中毒及相关危险因素的系统评价
Pharmacotherapy. 2017 Feb;37(2):187-194. doi: 10.1002/phar.1881. Epub 2017 Jan 16.
Zotero 插件